@EUBREAST

Account of the European Breast Cancer Research Association of Surgical Trialists - international non-profit association for breast cancer surgery research

 Milan, IT and Esslingen, DE
eubreast.org/
Joined January 2021
  • Tweets328
  • Following172
  • Followers335
117Media
🚨 NEW STUDY ALERT! 🚨 Recent data from the international #AXSANA (#EUBREAST03) study sheds critical light on the diagnostic performance of axillary ultrasound (AUS) after neoadjuvant chemotherapy (NACT) in initially node-positive breast cancer.
1
3
2
275
more replies
🔗 Read the full publication: doi.org/10.1016/j.ejca.2025.… 🙏 Huge thanks to the entire #AXSANA study team, 288 study sites across 26 countries, and all our collaborators and sponsors.
1
85
This work was supported by AGO-B, the Claudia von Schilling Foundation, Ehmann Foundation Savognin, AWOgyn, Endomag, A Hologic Company, Merit Medical Systems, Inc., and Mammotome. This milestone in axillary management would not be possible without your commitment!
86
🚨 Milestone Alert 🚨 #EUBREAST and #iBRANET are thrilled to welcome the first study site in South Africa to the #MELODY trial🙌 Thank you Mediclinic Morningside Hospital (Johannesburg) and Dr. Sarah Nietz for your work in making this exciting new collaboration happen🙏🏻
1
3
5
311
For more information, please visit: eubreast.org/melody/ #MELODY #Milestone #ASBrS #AWOgyn #AGO #KBCSG #OncoplasticBreastConsortium #SENATURK #BreastCancerResearch #TogetherWeCan #InternationalCollaboration

EUBREAST 04 (R) MELODY - MEthods for LOcalization of Different types of breast lesions - Eubreast

A prospective non-interventional multicenter cohort study to evaluate different imaging- guided methods for localization of malignant breast lesions

eubreast.org
52
🚨 NEW STUDY ALERT! 🚨 The international #AXSANA (#EUBREAST03) study brings new clarity to the clinical impact of lost axillary markers after neoadjuvant systemic therapy in breast cancer. The article was recently published in the European Journal of Surgical Oncology.
1
1
1
218
more replies
📣 Bottom line: Marker loss is rare but highly dependent on technique and experience. Clinical decision-making must be tailored accordingly. 🔗 Read the full open-access publication: doi.org/10.1016/j.ejso.2025.…
1
31
🙏 Huge thanks to the entire #AXSANA study team, all investigators across 288 study sites in 26 countries, and all our incredible collaborators and sponsors. This incredible work would not be possible without your dedication!
34
🔔 EUBREAST is proud to support the PartBreCon-Pro Study! 🔬 This international, prospective, multi-centre study is focused on partial breast reconstruction using chest wall perforator flaps (CWPF) following breast-conserving surgery for early breast cancer.
1
59
more replies
📩 Get involved today - join the PartBreCon-Pro Study led by Dr. Amit Agrawal! Contact the study team at partbrecon.pros@gmail.com 🌐 Learn more: eubreast.org/partbrecon-pro-…

PartBreCon-Pro Study (EUBREAST Supported) - Eubreast

June 2025, An international multi-centre PROspective study, including PROMS of PARTial BREast ReCONstruction with chest wall perforator flap A study by the

eubreast.org
1
28
🌍 Together, we aim to advance oncoplastic breast surgery through high-quality data and shared learning! #PartBreConPro #EUBREAST #BreastCancerResearch #ClinicalTrials #JoinTheFutureOfCare
28
🎉 CINDERELLA reaches 1,000 patients – and OSR was part of it! We are proud to celebrate the @SanRaffaeleMI team's valuable contribution to the recruitment efforts for the CINDERELLA clinical trial!
1
2
119
🌍 Cross-border collaboration in action! Our awesome Digital Strategy Team Representatives from Kazakhstan 🇰🇿 and Germany 🇩🇪 caught up with our SoMe Medical Supervisor at #ESMOBreast25! Nothing beats meeting in person to keep the energy high and the mission strong 💪💗 @myESMO
1
3
181
🙌#ESMOBreast25: Welcome to your international, multidisciplinary meeting solely dedicated to breast malignancies. Get ready for: ➡️Cutting-edge research ➡️Excellent networking opportunities ➡️Multidisciplinary discussions shaping the future 🔗 ow.ly/vgVk50VSh7b
3
10
1,567
Load more